AstraZeneca PLC closed 16.10% below its 52-week high of £133.88, which the company reached on September 3rd.

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

Invest Ontario is partnering with AstraZeneca (AZN) to expand the company’s global R&D hub in Mississauga. This C$820M investment underscores Ontario’s growing prominence in the life sciences ...

Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...

Jan 17 (Reuters) - The U.S. Food and Drug Administration has approved AstraZeneca (AZN.L), opens new tab and partner Daiichi Sankyo's (4568.T), opens new tab precision drug to treat a type of ...

Jan 17 (Reuters) - AstraZeneca (AZN.L), opens new tab has ... insurance fraud began three years ago and initially involved a small number of employees. It later escalated and some 100 now former ...

AstraZeneca (NASDAQ:AZN) is one of the biggest players in the healthcare sector, whose medicines save the lives of tens of thousands of people every year. In this article, I will share six reasons ...

A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for ...

FDA approves AstraZeneca's Datroway, reducing breast cancer progression risk by 37% per TROPION-Breast01 trial results. Datroway's safety profile remains consistent, with 4.2% ILD rate ...

A targeted cancer therapy from AstraZeneca’s alliance with Daiichi ... out as a leader in this setting and is expected to get a small piece of market share, the report said.